171 related articles for article (PubMed ID: 34595812)
1. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
Kazda C; Leohr J; Liu R; Reddy S; Dellva MA; Loh MT; Hardy T; Plum-Mörschel L
Diabetes Obes Metab; 2022 Feb; 24(2):196-203. PubMed ID: 34595812
[TBL] [Abstract][Full Text] [Related]
2. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
Leohr J; Kazda C; Liu R; Reddy S; Dellva MA; Matzopoulos M; Loh MT; Hardy T; Klein O; Kapitza C
Diabetes Obes Metab; 2022 Feb; 24(2):187-195. PubMed ID: 34605142
[TBL] [Abstract][Full Text] [Related]
3. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus.
Aronson R; Biester T; Leohr J; Pollom R; Linnebjerg H; LaBell ES; Zhang Q; Coutant DE; Danne T
Diabetes Obes Metab; 2023 Jul; 25(7):1964-1972. PubMed ID: 36974352
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
Linnebjerg H; Zhang Q; LaBell E; Dellva MA; Coutant DE; Hövelmann U; Plum-Mörschel L; Herbrand T; Leohr J
Clin Pharmacokinet; 2020 Dec; 59(12):1589-1599. PubMed ID: 32468447
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog
Leohr J; Dellva MA; Coutant DE; LaBell E; Heise T; Andersen G; Zijlstra E; Hermanski L; Nosek L; Linnebjerg H
Clin Pharmacokinet; 2020 Dec; 59(12):1601-1610. PubMed ID: 32468448
[TBL] [Abstract][Full Text] [Related]
6. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
Heise T; Linnebjerg H; Coutant D; LaBell E; Zijlstra E; Kapitza C; Bue-Valleskey J; Zhang Q; Dellva MA; Leohr J
Diabetes Obes Metab; 2020 Oct; 22(10):1789-1798. PubMed ID: 32436641
[TBL] [Abstract][Full Text] [Related]
7. Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog
Leohr J; Dellva MA; Carter K; LaBell E; Linnebjerg H
Clin Pharmacokinet; 2021 Nov; 60(11):1423-1434. PubMed ID: 34041713
[TBL] [Abstract][Full Text] [Related]
8. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
Leohr J; Dellva MA; LaBell E; Coutant DE; Arrubla J; Plum-Mörschel L; Zijlstra E; Fukuda T; Hardy T
Diabetes Obes Metab; 2024 Jan; 26(1):215-223. PubMed ID: 37814517
[TBL] [Abstract][Full Text] [Related]
9. Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog
Shiramoto M; Nasu R; Oura T; Imori M; Ohwaki K
J Diabetes Investig; 2020 May; 11(3):672-680. PubMed ID: 31816193
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
[TBL] [Abstract][Full Text] [Related]
11. Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy.
Malecki MT; Cao D; Liu R; Hardy T; Bode B; Bergenstal RM; Bue-Valleskey J
Diabetes Technol Ther; 2020 Nov; 22(11):853-860. PubMed ID: 32453647
[No Abstract] [Full Text] [Related]
12. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.
Klaff L; Cao D; Dellva MA; Tobian J; Miura J; Dahl D; Lucas J; Bue-Valleskey J
Diabetes Obes Metab; 2020 Oct; 22(10):1799-1807. PubMed ID: 32488923
[TBL] [Abstract][Full Text] [Related]
13. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
Warren M; Bode B; Cho JI; Liu R; Tobian J; Hardy T; Chigutsa F; Phillip M; Horowitz B; Ignaut D
Diabetes Obes Metab; 2021 Jul; 23(7):1552-1561. PubMed ID: 33687783
[TBL] [Abstract][Full Text] [Related]
14. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial.
Zhou J; Chen S; Cheng J; Zhu J; Lou Y; Bao Y; Jia W
Sci Bull (Beijing); 2022 Sep; 67(17):1785-1791. PubMed ID: 36546064
[TBL] [Abstract][Full Text] [Related]
15. Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis.
Jinnouchi H; Imori M; Nishiyama H; Imaoka T
Diabetes Ther; 2020 Sep; 11(9):2075-2088. PubMed ID: 32728833
[TBL] [Abstract][Full Text] [Related]
16. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
Bode BW; Garg SK; Norwood P; Morales C; Hardy T; Liu R; Ignaut D
Diabetes Technol Ther; 2021 Jan; 23(1):41-50. PubMed ID: 32640842
[No Abstract] [Full Text] [Related]
17. Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study.
Ma J; Yan X; Feng Q; Liu W; Pérez Manghi F; García-Hernández P; Wang G; Xu J; Yuan Y; Zhou Z
Diabetes Obes Metab; 2024 Jan; 26(1):311-318. PubMed ID: 37871985
[TBL] [Abstract][Full Text] [Related]
18. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China.
Yuan L; Luo Y; Luo Y; Ding B; Zhang P; Ma J; Wu J
Front Endocrinol (Lausanne); 2024; 15():1364585. PubMed ID: 38774225
[TBL] [Abstract][Full Text] [Related]
19. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
Bode B; Carlson A; Liu R; Hardy T; Bergenstal R; Boyd J; Morrett S; Ignaut D
Diabetes Technol Ther; 2021 Dec; 23(12):828-836. PubMed ID: 34270335
[No Abstract] [Full Text] [Related]
20. Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog
Miura J; Imori M; Nishiyama H; Imaoka T
Diabetes Ther; 2020 Sep; 11(9):2089-2104. PubMed ID: 32728832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
